Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseGuruFocus · 1 day ago
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseBusiness Wire · 1 day ago
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research · 2 days ago
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?The Motley Fool · 3 days ago
34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLCDefense World · 6 days ago
Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by First Citizens Bank & Trust Co.Defense World · Oct 17, 2026Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1).
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $1.63 | $1.21 | Miss |
| Apr 30, 2026 | $0.87 | $1.51 | Beat |
| Feb 12, 2026 | $1.16 | $0.82 | Miss |
| Oct 30, 2025 | $0.56 | $1.84 | Beat |
| Jul 31, 2025 | -$0.54 | -$0.51 | Beat |
| May 1, 2025 | -$0.89 | -$0.44 | Beat |